• 1
    Keating NL,O'Malley AJ,Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 44484456.
  • 2
    Braga-Basaria M,Dobs AS,Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clin Oncol. 2006; 24: 39793983.
  • 3
    D'Amico AV,Denham JW,Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 24202425.
  • 4
    Tsai H,D'Amico AV,Sadetsky N,Chen MH,Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 15161524.
  • 5
    D'Amico AV,Chen M,Renshaw AA,Loffredo M,Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289295.
  • 6
    Piccirillo JF,Tierney RM,Costas I,Grove L,Spitznagel ELJr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 24412447.
  • 7
    Roach MIII,Bae K,Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external bean radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585591.
  • 8
    Pilepich MV,Winter K,Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005; 61: 12851290.
  • 9
    Hanks GE,Pajak TF,Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol. 2003; 21: 39723978.
  • 10
    Beahrs OH,Henson DE,Hunter RVP. American Joint Committee on Cancer: Manual for Staging Cancer. 4th ed. Philadelphia, PA: JP Lippincott; 1992.
  • 11
    Kaplan EL,Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457500.
  • 12
    Gaynor JJ,Feuer EJ,Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993; 88: 400409.
  • 13
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 14
    Klein JP,Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: KleinJP,MoeschbergerML, eds. Survival Analysis: Techniques for Censored and Truncated Data.2nd ed. New York, NY: Springer; 2003: 243293.
  • 15
    Roach MIII,Hanks G,Thames HJr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965974.
  • 16
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 17
    D'Amico AV,Moul J,Carroll P,Sun L,Lubeck D,Chen M. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95: 13761383.
  • 18
    Klein JP. Modeling competing risks in cancer studies. Stat Med. 2006; 25: 10151034.
  • 19
    Beyer DC,McKeough T,Thomas T. Impact of short course neoadjuvant hormonal therapy on overall and cancer- specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 12991305.
  • 20
    Merrick GS,Butler WM,Wallner KE,Galbreath RW,Allen ZA,Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 669677.
  • 21
    Siagal CS,Gore JL,Krupski TL,Hanley J,Schonlau M,Litwin MS;the Urologic Disease in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110: 14931500.
  • 22
    Wirth MP,See WA,McLeod DG,Iversen P,Morris T,Carroll K;Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004; 172: 18651870.